Unleashing the power of p53: lessons from mice and men: Figure 1.
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
References http://www.genesdev.org/cgi/content/full/20/2/125#References This article cites 55 articles, 20 of which can be accessed free at: service Email alerting click here top right corner of the article or Receive free email alerts when new articles cite this article sign up in the box at the Topic collections (46 articles) Cancer and Disease Models Articles on similar topics can be found in the following collections
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Furthermore, Nutlins can suppress growth of established tumor xenographs in nude mice to the same extent as treatment with doxorubicin (Vassilev et al. 2004).”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379 · cited 1×
“A higher amount of Mdm2 would both degrade the extra p53 protein and also the other negative regulator of p53, MdmX GENES & DEVELOPMENT 127 (Chen et al. 2005; Okamoto et al. 2005; Pereg et al. 2005), thus bringing p53 down to levels found in wild-type cells, but such p53 would be relatively more…”
BackgroundStructure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · cited 1×
“The remarkable fact that the Mdm2–p53 interaction is mediated by three hydrophobic residues (Kussie et al. 1996) suggested that Mdm2 might be a suitable target for small compounds that could uncouple p53 and Mdm2, leading to elevation in p53 activity (Moll and Zaika 2000; Vassilev 2004).”
BackgroundAmplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“In general, protein–protein interactions are viewed as poor targets for drug design due to the fact that protein complexes usually have large interacting surfaces not easily disturbed by small molecules (Arkin and Wells 2004).”
Backgroundp53 mutant mice that display early ageing-associated phenotypes
Tyner, S. D., Venkatachalam, S., Choi, J., Jones, S., Ghebranious, N., Igelmann, H., Lu, X., Soron, G., Cooper, B., Brayton, C., et al. (2002) · Nature · doi:10.1038/415045a · Cited by 1,459
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53
de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1×
“…maintaining the p53–Mdm2–MdmX circuitry, perhaps the most compelling being the fact that it is not possible to produce viable Mdm2- or Mdmx-null mice unless either are generated in a p53-null background (Jones et al. 1995; Montes de Oca Luna et al. 1995; Parant et al. 2001; Migliorini et al. 2002).”
BackgroundRescue of embryonic lethality in Mdm2-deficient mice by absence of p53
Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280
Bond, G. L., Hu, W., Bond, E. E., Robins, H., Lutzker, S. G., Arva, N. C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., et al. (2004) · Cell · doi:10.1016/j.cell.2004.11.022 · Cited by 1,265 · cited 3×
“A landmark study from the group of A. Levine has shed new light on the mechanism of Mdm2 overexpression in some hereditary and sporadic tumors (Bond et al. 2004).”
BackgroundResultp53 isoforms can regulate p53 transcriptional activity
Bourdon, J.-C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D. P., Saville, M. K., & Lane, D. P. (2005) · Genes & Development · doi:10.1101/gad.1339905 · Cited by 810 · cited 1×
“In fact, it is now known that, like its p63 and p73 homologs, p53 can be expressed as multiple isoforms (including p44) with different N and C termini that are likely to have different activities and interactions (Bourdon et al. 2005; Mills 2005; Prives and Manfredi 2005; Rohaly et al. 2005).”
Background
Cited by
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
“A wealth of studies have delved into their interactions with p53 and have been well reviewed (Marine et al., 2006, 2007; Poyurovsky and Prives, 2006; Toledo and Wahl, 2006).”
BackgroundSelf-citationVousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
p53 Regulates Mitochondrial Respiration
Matoba, S., Kang, J.-G., Patino, W. D., Wragg, A., Boehm, M., Gavrilova, O., Hurley, P. J., Bunz, F., & Hwang, P. M. (2006) · Science · doi:10.1126/science.1126863 · Cited by 1,650
Mutant p53: one name, many proteins
Freed-Pastor, W. A., & Prives, C. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,247
Self-citationp53 Activation by Knockdown Technologies
Robu, M. E., Larson, J. D., Nasevicius, A., Beiraghi, S., Brenner, C., Farber, S. A., & Ekker, S. C. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030078 · Cited by 999
Divorcing ARF and p53: an unsettled case
Sherr, C. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1954 · Cited by 595
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Coping with stress: multiple ways to activate p53
Horn, H. F., & Vousden, K. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210263 · Cited by 522
Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways
Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321
“Clearly the relative levels of p53 and MDM-2 are critical to the phenotype under study and are themselves regulated by a variety of other gene products that can influence that phenotype (Poyurovsky and Prives 2006).”
BackgroundBensaad, K., & Vousden, K. H. (2007) · Trends in Cell Biology · doi:10.1016/j.tcb.2007.04.004 · Cited by 305
Trim24 targets endogenous p53 for degradation
Allton, K., Jain, A. K., Herz, H.-M., Tsai, W.-W., Jung, S. Y., Qin, J., Bergmann, A., Johnson, R. L., & Barton, M. C. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813177106 · Cited by 292
Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283
“Therefore, blocking the p53-MDM2 interaction is expected to overcome the oncogenic consequences of MDM2 overproduction and to restore p53 function (12, 13).”
BackgroundLi, M., Zhang, Z., Hill, D. L., Wang, H., & Zhang, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3066 · Cited by 274
Chen, D., Zhang, Z., Li, M., Wang, W., Li, Y., Rayburn, E. R., Hill, D. L., Wang, H., & Zhang, R. (2007) · Oncogene · doi:10.1038/sj.onc.1210327 · Cited by 261
Trade-Offs (and Constraints) in Organismal Biology
Garland, T., Downs, C. J., & Ives, A. R. (2022) · Physiological and Biochemical Zoology · doi:10.1086/717897 · Cited by 256
CDK8 Is a Stimulus-Specific Positive Coregulator of p53 Target Genes
Donner, A. J., Szostek, S., Hoover, J. M., & Espinosa, J. M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.026 · Cited by 252
Relevance of the p53–MDM2 axis to aging
Wu, D., & Prives, C. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.187 · Cited by 215
Self-citationRibosomal Protein S7 Is Both a Regulator and a Substrate of MDM2
Zhu, Y., Poyurovsky, M. V., Li, Y., Biderman, L., Stahl, J., Jacq, X., & Prives, C. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.014 · Cited by 206
“MDM2 is a crucial negative regulator of the p53 tumor suppressor protein (Brooks and Gu, 2006; Poyurovsky and Prives, 2006; Toledo and Wahl, 2006).”
Self-citationPoyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z., Pavletich, N., & Prives, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601465 · Cited by 203
Liu, J., Chung, H., Vogt, M., Jin, Y., Malide, D., He, L., Dundr, M., & Levens, D. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.11 · Cited by 141
“Unlike HAUSP, which targets both p53 and Hdm2 (Vogelstein et al, 2000; Brooks and Gu, 2004, 2006; Poyurovsky and Prives, 2006), USP29 removed ubiquitin much more efficiently from the former.”
BackgroundGannon, H. S., Donehower, L. A., Lyle, S., & Jones, S. N. (2011) · Developmental Biology · doi:10.1016/j.ydbio.2011.02.007 · Cited by 87
“Therefore, the role of p53 in regulating accelerated aging in mice remains a matter of much debate (Poyurovsky and Prives, 2006; Vijg and Hasty, 2005; Gentry and Venkatachalam, 2005).”
BackgroundA distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097
Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85
“Indeed, prior work has shown that in human cancer cell lines or xenografts such inhibitors can elicit potent anti-tumor effects as a result of induc- tion of cell cycle growth arrest and an apoptotic response (Poyurovsky and Prives, 2006; Brown et al., 2009; Cheok et al., 2011).”
BackgroundLee, H.-R., Toth, Z., Shin, Y. C., Lee, J.-S., Chang, H., Gu, W., Oh, T.-K., Kim, M. H., & Jung, J. U. (2009) · Journal of Virology · doi:10.1128/jvi.02353-08 · Cited by 78
“pBabe-vIRF4 (1-605)/V5 and then selected using 2 g/ml of puromycin (Sigma).”
BackgroundMethodInfluentialDiscovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy
Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.072 · Cited by 60
Kulkarni, A., & Das, K. C. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00004.2008 · Cited by 56
Metadata
- Authors
- Poyurovsky, M. V., & Prives, C.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2006-01-15
- Volume
- 20
- Issue
- 2
- Pages
- 125-131
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2172238284
- Cited by
- 96
- References
- 22
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.